ARTICLE | Clinical News
RGX-104: Ph I started
January 12, 2017 12:46 AM UTC
Rgenix began an open-label, dose-escalation, dose-expansion, U.S. Phase I trial to evaluate oral RGX-104 in about 80 patients. Rgenix has exclusive, worldwide rights to RGX-104 from GlaxoSmithKline....
BCIQ Target Profiles